Publication | Closed Access

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

OncologyDose Escalation TrialMedicinePathologyMolecular OncologyAnti-cancer AgentTargeted TherapyAdvanced Solid CancersCancer TreatmentPharmacologyRadiation OncologySecond Generation AntisenseNovel TherapyCancer Research